Research conducted at Oxford University suggests that COVID-19 may be causing lung-damage in patients that can be detected over three months after the initial infection.
Xenon Pharmaceuticals announced Friday that a Phase II study of the experimental drug XEN801 for the treatment of moderate to severe facial acne failed to meet its primary endpoint. Shares in the company fell as much as 45 percent on the news.